论文部分内容阅读
[目的]研究枢丹和格拉司琼在甲状腺癌根治术患者术后的抗呕吐作用 ,并比较两者对术后恶心呕吐(PONV)的预防效果。[方法]选择甲状腺癌根治术患者90例 ,随机分为枢丹组(4mg,n=30)、格拉司琼组(3mg,n=30)和安慰剂组(生理盐水 ,n=30) ,诱导前静推枢丹或格拉司琼或安慰剂 ,双盲法观察术后24小时恶心、呕吐的发生率。[结果]枢丹组恶心、呕吐的发生率(23 % ,17 %)与格拉司琼组(20 % ,13 %)无显著性差异(P>0 05) ,用药组恶心、呕吐的发生率明显低于安慰剂组(67 % ,57 %;P<0 01)。[结论]枢丹和格拉司琼均能有效地预防甲状腺癌根治术后的恶心、呕吐 ,两者对PONV的预防效果无明显差别。
[Objective] To study the anti-emetic effect of both Shuandan and granisetron in postoperative patients with thyroid cancer undergoing radical operation, and to compare their preventive effects on postoperative nausea and vomiting (PONV). [Methods] Ninety patients undergoing radical thyroidectomy were randomly divided into four groups (4mg, n = 30), granisetron (3mg, n = 30) and placebo (n = 30) Thrombolysis or gestrinone or placebo was given before induction, and the incidence of nausea and vomiting was observed 24 hours after operation by double-blind method. [Results] The incidence of nausea and vomiting (23%, 17%) in the DH group was not significantly different from that in granisetron (20%, 13%) (P> 0.05). The incidence of nausea and vomiting Significantly lower than placebo (67%, 57%; P <0.01). [Conclusion] Both Shuandan and granisetron can effectively prevent nausea and vomiting after radical operation of thyroid cancer. There is no significant difference between the two groups in the prevention of PONV.